A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/− ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy
| Autor: | Michael Fried, Larry Michael, Gary P. Wang, Yiran B Hu, Mitchell L. Shiffman, David R. Nelson, Robert H. Brown, Monika Vainorius, Anna S.F. Lok, Giuseppe Morelli, Federico Hinestrosa, Joy Peter, I. Willner, Jens Kort, M.S. Sulkowski, Mohamed Hassan, Rajender Reddy |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Hepatology Sofosbuvir business.industry Ribavirin Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry Hcv genotype 1 Internal medicine Medicine 030211 gastroenterology & hepatology 030212 general & internal medicine Open label Glecaprevir / pibrentasvir business NS5A medicine.drug |
| Zdroj: | Journal of Hepatology. 68:S104 |
| ISSN: | 0168-8278 |
| DOI: | 10.1016/s0168-8278(18)30427-6 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect